View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

Soleno Therapeutics Provides Corporate Update and Reports First Quarte...

Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results REDWOOD CITY, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and reported financial results for the first quarter ended March 31, 2024. First Quarter 2024 and Recent Corporate Highlights Closed on approximately $158.7 million underwritten public offering of 3,450,000 shares of common stock at a public of...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: May 4, 2024

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Soleno Therapeutics Announces Pricing of Approximately $138 Million Pu...

Soleno Therapeutics Announces Pricing of Approximately $138 Million Public Offering Of Common Stock REDWOOD CITY, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Nasdaq: SLNO), (“Soleno” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today the pricing of the underwritten public offering of 3,000,000 shares of its common stock at a public offering price of $46.00 per share. The gross proceeds of the public offering are expected to be approximately $138.0 million, before deducting ...

 PRESS RELEASE

Soleno Therapeutics Announces Proposed Public Offering of Common Stock

Soleno Therapeutics Announces Proposed Public Offering of Common Stock REDWOOD CITY, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Nasdaq:SLNO), ("Soleno" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today that it intends to offer and sell shares of its common stock in an underwritten public offering. In addition, Soleno intends to grant the underwriters a 30-day option to purchase an additional number of shares of common stock equal to 15% of the aggregate number of shares o...

 PRESS RELEASE

Athira Pharma to Participate in Upcoming May Conferences

Athira Pharma to Participate in Upcoming May Conferences BOTHELL, Wash., May 02, 2024 (GLOBE NEWSWIRE) --  (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that Company management will participate in the following upcoming investor conferences in May. Sidoti May 2024 Virtual Investor ConferenceFormat: Company PresentationDate and Time: Wednesday, May 8, 2024, from 10:45 a.m. - 11:15 a.m. ET Location: Virtual The Citizens JMP Life Sciences ConferenceFormat: Fireside...

Wedbush Research
  • Wedbush Research
MTB M&T BANK CORPORATION
SIVB SVB FINANCIAL GROUP
USB U.S. BANCORP
ZION ZIONS BANCORPORATION N.A.
WTFC WINTRUST FINANCIAL CORPORATION
WING WINGSTOP INC.
WBS WEBSTER FINANCIAL CORPORATION
WAL WESTERN ALLIANCE BANCORP
VLY VALLEY NATIONAL BANCORP
TTWO TAKE-TWO INTERACTIVE SOFTWARE INC.
TCBI TEXAS CAPITAL BANCSHARES INC.
SBNY SIGNATURE BANK
RF REGIONS FINANCIAL CORPORATION
PZZA PAPA JOHN'S INTERNATIONAL INC.
PPBI PACIFIC PREMIER BANCORP INC.
PB PROSPERITY BANCSHARES INC.(R)
NYCB NEW YORK COMMUNITY BANCORP INC.
KEY KEYCORP
JACK JACK IN THE BOX INC.
HMST HOMESTREET INC.
HBAN HUNTINGTON BANCSHARES INCORPORATED
HAFC HANMI FINANCIAL CORPORATION
FRC FIRST REPUBLIC BANK
FITB FIFTH THIRD BANCORP
FHN FIRST HORIZON CORPORATION
FFWM FIRST FOUNDATION
EWBC EAST WEST BANCORP INC.
ETSY ETSY INC.
DIN DINE BRANDS GLOBAL INC.
CVBF CVB FINANCIAL CORP.
CUBI CUSTOMERS BANCORP INC.
CTSH COGNIZANT TECHNOLOGY SOLUTIONS CORPORATION CLASS A
COLB COLUMBIA BANKING SYSTEM INC.
CHUY CHUY'S HOLDINGS INC.
CFG CITIZENS FINANCIAL GROUP INC.
CATY CATHAY GENERAL BANCORP
CAKE CHEESECAKE FACTORY INCORPORATED
BZH BEAZER HOMES USA INC.
BXP BOSTON PROPERTIES INC.
BKU BANKUNITED INC.
BANC BANC OF CALIFORNIA INCORPORATED
GRBK GREEN BRICK PARTNERS
CFR CULLEN/FROST BANKERS INC.
BOKF BOK FINANCIAL CORPORATION
CMA COMERICA INCORPORATED
EA ELECTRONIC ARTS INC.
SLM SLM CORP
TSC TRISTATE CAPITAL HOLDINGS INC
ZNGA ZYNGA INC. CLASS A
HOPE HOPE BANCORP INC.
CVNA CARVANA CO. CLASS A
FCNCA FIRST CITIZENS BANCSHARES INC. CLASS A
ZG ZILLOW GROUP INC. CLASS A
TENB TENABLE HOLDINGS
AX AXOS FINANCIAL INC.
UBER UBER TECHNOLOGIES INC.
LC LENDINGCLUB CORP
SI SILVERGATE CAPITAL
U UNITY SOFTWARE
DASH DOORDASH
SOFI SOFI TECHNOLOGIES INC
APP APPLOVIN CORP
NAPA DUCKHORN PORTFOLIO INC (THE)
BROS DUTCH BROS INC
CAVA CAVA GROUP INC
 PRESS RELEASE

AMWELL ANNOUNCES RESULTS FOR FIRST QUARTER 2024

AMWELL ANNOUNCES RESULTS FOR FIRST QUARTER 2024 Boston, May 01, 2024 (GLOBE NEWSWIRE) -- (NYSE: AMWL) a small-cap, growth healthcare company and a leading provider of healthcare software as a service, today announced financial results for the first quarter ended March 31, 2024. Visit Amwell’s investor relations website at to view the first quarter 2024 earnings report. The company will host a conference call to discuss its financial results today at 5 p.m. ET, Wednesday, May 1. The call can be accessed via a live audio webcast at or by dialing 1-888-510-2008 for U.S. participants or...

 PRESS RELEASE

Soleno Therapeutics Announces Peer-Reviewed Publication of Data Compar...

Soleno Therapeutics Announces Peer-Reviewed Publication of Data Comparing DCCR Treatment to the Natural History of Prader-Willi Syndrome Statistically Significant Improvements with DCCR Compared to Natural History of PWS from the PATH for PWS Study in Hyperphagia and PWS-related Behaviors REDWOOD CITY, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the publication of the comparison of results from the Company’s Phase ...

 PRESS RELEASE

Soleno Therapeutics Receives Breakthrough Therapy Designation from U.S...

Soleno Therapeutics Receives Breakthrough Therapy Designation from U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome (PWS) First Ever Breakthrough Designation for a Drug Being Developed for PWS Designation is Based on Data from the Phase 3 Program for DCCR Planned Submission of a New Drug Application (NDA) for DCCR Remains on Track for Mid-2024 REDWOOD CITY, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of...

 PRESS RELEASE

Amwell Releases 2024 Corporate Responsibility Report

Amwell Releases 2024 Corporate Responsibility Report Report demonstrates company progress toward enabling digital healthcare with purpose Boston, April 29, 2024 (GLOBE NEWSWIRE) -- ® (NYSE: AMWL), a leader in hybrid care enablement, today announced the release of its 2024 Corporate Responsibility Report, which details the company’s latest progress across environmental, social, and governance (ESG) topics and highlights Amwell’s growing positive impact on key stakeholders and the communities it serves. “Corporate responsibility is fundamental to our mission to transform healthcare, wh...

 PRESS RELEASE

HOME FEDERAL BANCORP, INC. OF LOUISIANA REPORTS RESULTS OF OPERATIONS ...

HOME FEDERAL BANCORP, INC. OF LOUISIANA REPORTS RESULTS OF OPERATIONS FOR THE THREE AND NINE MONTHS ENDED MARCH 31, 2024 Shreveport, Louisiana , April 26, 2024 (GLOBE NEWSWIRE) -- Home Federal Bancorp, Inc. of Louisiana (the “Company”) (Nasdaq: HFBL), the holding company of Home Federal Bank, reported net income for the three months ended March 31, 2024, of $732,000 compared to net income of $1.1 million reported for the three months ended March 31, 2023. The Company’s basic and diluted earnings per share were $0.24 for the three months ended March 31, 2024, compared to basic and diluted ...

 PRESS RELEASE

Amwell to Participate in Upcoming Investor Conference

Amwell to Participate in Upcoming Investor Conference Boston, April 25, 2024 (GLOBE NEWSWIRE) -- ® (NYSE: AMWL), a leader in hybrid care enablement, announced that the company will participate in the Needham Technology, Media and Consumer Conference.  Robert Shepardson, Amwell chief financial officer, will participate in a fireside chat on Tuesday, May 14, at a time to be determined, along with one-on-one investor meetings throughout the day.   An audio webcast of the fireside chat will be available at   About Amwell   Amwell is a leading hybrid care delivery enablement platform ...

 PRESS RELEASE

Brookline Bancorp Announces First Quarter Results

Brookline Bancorp Announces First Quarter Results Net Income of $14.7 million, EPS of $0.16 Quarterly Dividend of $0.135 BOSTON, April 24, 2024 (GLOBE NEWSWIRE) -- Brookline Bancorp, Inc. (NASDAQ: BRKL) (the “Company”) today announced net income of $14.7 million, or $0.16 per basic and diluted share, for the first quarter of 2024, compared to net income of $22.9 million, or $0.26 per basic and diluted share, for the fourth quarter of 2023, and net income of $7.6 million, or $0.09 per basic and diluted share, for the first quarter of 2023. Paul Perrault, Chairman and CEO, commented on t...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: April 20, 2024

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing R...

Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) REDWOOD CITY, Calif., April 19, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced, as required by Nasdaq Stock Market rules, the grant of inducement awards to six new employees. The independent members of the Board of Directors of Soleno approved the grant of non-qualified stock options to purchase 96,500 shares of common stock to six employees as an ind...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch